ArticleWorld journal of surgical oncology2025
Prophylactic hyperthermic intraperitoneal chemotherapy is associated with improved disease-free survival in pathologic T4 colorectal cancer: a propensity score-matched cohort study.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundPathologic T4 colorectal cancer (CRC) carries a high risk of peritoneal recurrence despite curative resection. Early postoperative hyperthermic intraperitoneal chemotherapy (HIPEC) may enhance intraperitoneal cytotoxic exposure and improve recurrence control. We evaluated whether prophylactic HIPEC administered within one week of surgery improves outcomes in pathologic T4 (pT4) CRC.
methodsWe conducted a single-center, retrospective cohort study of consecutive patients with pathologically confirmed pT4 colorectal adenocarcinoma (2018-2022). Prophylactic HIPEC consisted of intraperitoneal 5-fluorouracil (650 mg/m
resultsAmong 690 screened patients, 471 were eligible (155 HIPEC; 316 non-HIPEC). In the matched cohort, Kaplan-Meier comparisons were not statistically significant for DFS (log-rank p = 0.074) or OS (p = 0.460). In multivariable Cox models, HIPEC was associated with improved DFS (hazard ratio [HR] = 0.58, 95% confidence interval [CI] 0.38-0.88; p = 0.012) but not OS (HR = 0.72, 95% CI 0.41-1.24; p = 0.237). Peritoneal, hepatic, and pulmonary recurrence rates were comparable between groups, while other-site recurrence was lower with HIPEC (5.1% in HIPEC and 13.1% in non-HIPEC; p = 0.032). Results were directionally consistent across sensitivity analyses.
conclusionsProphylactic HIPEC delivered within one postoperative week was associated with improved DFS, without an observed OS advantage over the study interval, in patients with pT4 CRC. These data support selective use of early postoperative HIPEC as an adjunct to curative resection, with patient counseling focused on anticipated gains in recurrence control and the current uncertainty regarding long-term survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.